Evidence map›Paper›PMID 41447401›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Detection of inflammation and glial cell-related biomarkers in adults with spinal muscular atrophy receiving nusinersen therapy.

Doruk Arslan, Zeynep Ergul-Ulger, Sibel Goksen, Berin Inan, Gunes Esendagli, Sevim Erdem-Ozdamar, Ersin Tan, Can Ebru Bekircan-Kurt

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Doruk ArslanDepartment of Neurology, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.
Zeynep Ergul-UlgerNeuromuscular Diseases Research Laboratory, Department of Neurology, School of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey.
Sibel GoksenDepartment of Medical and Surgical Research, Institute of Health Sciences, School of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey.
Berin InanDepartment of Neurology, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.
Gunes EsendagliDepartment of Medical and Surgical Research, Institute of Health Sciences, School of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey.
Sevim Erdem-OzdamarDepartment of Neurology, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.
Ersin TanDepartment of Neurology, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.
Can Ebru Bekircan-KurtDepartment of Neurology, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey. canebru@yahoo.co.uk.ORCID http://orcid.org/0000-0003-2355-6979

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPathogenesis of spinal muscular atrophy (SMA) is not limited to motor neuron degeneration and many different cells and tissue types, especially glial cells and neuroinflammation, are thought to play a role in the process. We aimed to define the contribution of glial cell and neuroinflammation-related molecules to the SMA process and to identify biomarkers that may be diagnostic and/or predict the clinical response to nusinersen treatment.

methodsTwenty-four adult SMA patients receiving nusinersen treatment and twelve healthy subjects were included. Four molecules associated with glial cells (GFAP and GDNF) and neuroinflammatory activity (YKL-40 and IL-6) were analyzed.

resultsSMA patients had higher cerebrospinal fluid (CSF) GFAP and IL-6 levels (p < 0.05) and lower GDNF levels (p < 0.05) compared to the controls. CSF levels of IL-6 and YKL-40 decreased and GDNF increased under nusinersen treatment (p < 0.05). Higher baseline CSF GFAP levels were associated with more favorable clinical responses to treatment. DISCUSSION: GFAP is a marker of both diagnostic and prognostic importance for SMA disease, and higher levels are associated with better clinical outcome. New therapies targeting glial cells and anti-inflammatory agents may have a positive impact on the clinical utility of current treatments.

Indexed as

Chitinase-3-Like Protein 1Glial Cell Line-Derived Neurotrophic FactorGlial Fibrillary Acidic ProteinInterleukin-6Muscular Atrophy, SpinalNeurogliaOligonucleotidesAdultBiomarkersFemaleHumansMaleMiddle AgedYoung AdultBiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1GDNF protein, humanGFAP protein, humanGlial Cell Line-Derived Neurotrophic FactorGlial Fibrillary Acidic ProteinIL6 protein, humanInterleukin-6nusinersenOligonucleotidesAstrocyteBiomarkerGFAPNeuroinflammationNusinersen

Identifiers

PMID41447401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.